Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference
March 20 2018 - 8:00AM
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage
biotechnology company that designs and develops innovative human
enzyme therapeutics for patients with rare genetic diseases and
cancer, today announced that it will present a corporate update at
the 17th Annual Needham Healthcare Conference in New York on
Tuesday, March 27 at 9:00 a.m. ET.
To access the live and archived webcast of the presentation,
please visit the Presentations & Events section of the Aeglea
BioTherapeutics investor relations website. Please connect to the
website at least 15 minutes prior to the presentation to allow for
any software download that may be necessary. The replay of the
webcast will be available for 30 days thereafter.
About Aeglea BioTherapeutics Aeglea is a
clinical-stage biotechnology company that designs and develops
innovative human enzyme therapeutics for patients with rare genetic
diseases and cancer. The Company is developing pegzilarginase, its
lead investigational therapy, for the treatment of Arginase 1
Deficiency, as monotherapy in arginine-dependent cancers and in
combination with an immune checkpoint inhibitor for small cell lung
cancer. In addition, Aeglea has an active research pipeline of
other human enzyme-based approaches in both therapeutic areas. For
more information, please visit http://aegleabio.com.
Media Contact: David Calusdian Sharon Merrill
Associates 617.542.5300 AGLE@investorrelations.com
Investor Contact: Charles N. York II Chief
Financial Officer Aeglea BioTherapeutics
investors@aegleabio.com
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Apr 2023 to Apr 2024